- Veröffentlichungsnummer:
- 11 Publication number:
- 0 495 079
- Numéro de publication:

Internationale Anmeldung veræffentlicht durch die Weltorganisation fßr geistiges Eigentum unter der Nummer:

WO 92/02967 (art.158 des EPf).

International application published by the World Intellectual Property Organisation under number:

WO 92/02967 (art.158 of the EPC).

Demande internationale publieà par l'Organisation Mondiale de la Propriàtà sous le numèro:

WO 92/02967 (art.158 de la CBE).

BEST AVAILABLE COPY

BNSDOCID: <EP____0495079A0_I_>

THIS PAGE BLANK (USPTO)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

			· · ·
(51) International Patent Classification 5:		(11) International Publication Number:	WO 92/02967
H01M 6/16	A1	(43) International Publication Date:	20 February 1992 (20.02.92)

(21) International Application Number:

PCT/US91/05618

(22) International Filing Date:

7 August 1991 (07.08.91)

(30) Priority data:

566,010

10 August 1990 (10.08.90) US

(71) Applicant: MEDTRONIC, INC. [US/US]; 7000 Central Avenue N.E., Minneapolis, MN 55432 (US).

(72) Inventors: BERBERICK, David, K.; 10177 Nathan Lane, Maple Grove, MN 55369 (US). CRETZMEYER, John, W.; 7604 Oliver Avenue South, Richfield, MN 55423 (US). MERRITT, Donald, R.; 3806 Woodbine Lane, Brookyln Center, MN 55429 (US). SKARSTAD, Paul, M.; 2415 Graland Lane, Plymouth, MN 55447 (US). WEISS, Douglas, J.; 3742 114th Lane Northwest, Coon Rapids, MN 55433 (US).

(74) Agents: LATHAM, Daniel, W. et al.; Medtronic, Inc., 7000 Central Avenue N.E., Minneapolis, MN 55432 (US).


(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: IMPROVED ELECTROLYTE FOR LITHIUM-MANGANESE OXIDE CELLS AND THE LIKE



(57) Abstract

An improved electrolyte for electrochemical cells including as a cosolvent for the cell electrolyte salt an amount of diglyme; ethyl diglyme; ethyl glyme; triglyme, tetraglyme and higher glymes; dimethoxymethane; 1,2-dimethoxypropane; dimethoxy THF or mixtures thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	· MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	· NL	Netherlands '
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	π	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic	SE	Sweden
CH	Switzerland		of Korea	SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korca	su+	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TG	Togo
DE	Germany	LU.	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

⁺ It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

DK

Denmark

IMPROVED ELECTROLYTE FOR LITHIUM-MANGANESE OXIDE CELLS AND THE LIKE

Technical Background

This invention relates to an improved electrolyte for non-aqueous electrochemical cells, specifically of the lithium/manganese dioxide type. However, it also relates more generally to a variety of such cells of differing chemistry which may be generally characterized as having active metal anodes, active porous solid cathodes, a separator between the electrodes and a non-aqueous liquid electrolyte permeating the separator and in contact with the anode and cathode. The electrolyte includes a salt of the anode metal and an organic solvents therefor.

10

15

20

5

Such cells, in hermetically sealed condition, are particularly useful as power sources for medical devices. A preferred form for such cells in medical devices includes a flat sided metal container or can. Hermeticity is achieved by welding the can closed.

In discharging such cells the cell components are known to undergo a variety of chemical reactions which cause formation of various gases such as methane, resulting in swelling of the cell container. This is particularly disadvantageous in the sealed flat sided cells preferred for medical use. Moreover, these cells have been found to i. k stability at elevated temperatures, such as autoclave temperatures, and thus have not been as, useful as desired for various medical applications such as powering heart pacemakers and the like. Also, it has recently been discovered that such cells undergo on discharge the formation of corrosion products at least some of which form on the anode and detrimentally affect efficiency of operation.

It is a purpose of this invention to significantly reduce each of these aforenoted negative characteristics while maintaining and even improving the desirable characteristics of these cells and providing them with longer useful lives.

10

15

20

Summary of the Invention

The invention accomplishes these purposes by including within the electrolyte as a new cosolvent an amount of diglyme; ethyl diglyme; ethyl glyme; triglyme, tetraglyme and higher glymes; dimethoxymethane; 1,2-dimethoxypropane; dimethoxy THF or mixtures thereof. In addition to a lower susceptibility to methane formation, diglyme, ethyl diglyme the other glycol ethers set forth in accordance with this invention are less volatile than glyme. That is, they have lower vapor pressure at a given temperature. Consequently, they are advantageous for medical applications in batteries used in devices that might be autoclaved.

Prior Art Background

In so far as can be determined, ethyl diglyme or the other cosolvents mentioned above have not been suggested for use in cells of the aforementioned type for use as a cosolvent. Diglyme has been suggested in U.S. Pat. 4,279,972 issued to Moses on July 21, 1981, as a sole electrolyte solvent and such use has been referred to in U.S. Pat. 4,328,288, issued to Taylor on May 4, 1981. However, no suggestion has been found for using it as a cosolvent in such cells. Propylene carbonate (PC) is described as being a preferred solvent.

One problem with pure glycol ethers as solvents as described in the Moses Pat.

No. 4,279,972 is that the solubility of many useful salts is low. This results in a low-conductivity electrolyte. This is illustrated by the values in the Table included below. For example, LiClO₄ is saturated at 0.07M in pure diglyme with a conductivity of 3.1 x

10 ⁴S/Cn. The conductivity of 1M LiClO₄ in a mixture of diglyme and propylene carbonate (PC), 50:50 by volume, is 9.0 X 10⁻³ S/cm, a factor of nearly 30 greater. A second problem with the use of pure diglyme as described in Moses is that there is a tendency toward methane evolution in Li/Mn°₂ cells which increases dramatically with increasing diglyme concentration.

TABLE

CONDUCTIVITIES OF THE SYSTEM PC/DIGLYME/LiClO₄

		[LiClO ₄]	
10	Solvent Blend	<u>(M)</u>	$(S/cm \times 101^3)$
	pure PC	2.41 (sat.)	0.26
	9OPC/10 diglyme	3.08 (sat.)	0.46
	75PC/25 diglyme	2.85 (sat.)	0.50
	5OPC/50 diglyme	3.17 (sat.)	0.75
15	25PC/75 diglyme	1.28 (sat.)	9.0
	1OPC/90 diglyme	0.84 (sat.)	8.1
	pure diglyme	0.07 (sat.)	0.31
	pure PC	0.25M	3.5
	pure PC	1.OM	5.5
20	9OPC/10 diglyme	0.25	4.5
	9OPC/10 diglyme	1.0	7.0
	7OPC/30 diglyme	0.25	4.9

		•	
		. 4	
	7OPC/30 diglyme	1.0	9.0
	5OPC/50 diglyme	0.25	5.0
	5OPC/50 diglyme	1.0	9.0
	3OPC/70 diglyme	0.25	4.9
5	3OPC/70 diglyme	1.0	9.5
	1OPC/90 diglyme	0.25	3.4
	1OPC/90 diglyme	0.76	7.7

Problems that exist with the use of pure PC as solvent are twofold: 1) electrolytes made with pure PC as solvent fail to wet microporous polypropylene separators effectively and consequently, the separator becomes a high resistance barrier in the cell and 2) use of pure PC leads to increased CO₂ formation in undischarged batteries which contain small amounts of water, as do many non-aqueous Li/MnO₂ cells. This is probably the gas which the Moses patent purports to eliminate.

15

10

The standard electrolyte solvent blend PC/glyme 50:50 provides a solvent in which the salt is amply soluble, which permeates a microporous polypropylene separator, such as Celgarc (a trade name of Celanese Corporation for their microporous non-woven polypropylene product) and in which CO₂ evolution can easily be eliminated. However, the propensity for methane formation with MnO₂ is still too high. Substitution of ethers of the invention maintains the good properties of PC/glyme and reduces the gassing via CH₄

Brief Description of the Drawings

Figs. 1 - 11 are various graphs illustrating data taken in various experiments to illustrate effects of the invention.

5

10

15

Description of the Preferred Embodiments

The general chemistry involved in the cells of concern herein is already known and has been described by others. For example, the following U.S. patents describe a variety of compositions for such cells: 4,279,972; 4,328,288 (both of which are already referred to hereinabove); 4,133,856 issued to Ikeda et al on January 9, 1979; 4,310,609 issued to Liang et al on January 12, 1982; 4,391,729 issued to Liang et al on July 5, 1983 and 4,830,940 issued to Keister et al on May 16, 1989, all of which are incorporated herein by reference.

This invention is applicable to all the compositions and material combinations described in the prior art but is particularly useful in the lithium/manganese dioxide, lithium/CF_x and lithium/silver vanadium oxide type cells having an electrolyte formed by dissolving lithium perchlorate (LiClO₄ or LIBF₄ in the case of LICF_x cells) in propylene carbonate (PC) solvent and including in accordance with this invention an amount of diglyme, ethyl diglyme; ethyl glyme; triglytne, tetraglyme and higher glymes; dimethoxy-methane, 1,2-dimethoxypropane; dimethoxy THF or mixtures thereof, as a cosolvent along with the PC solvent or the like.

10

15

An effective minimal amount of the cosolvent combination with PC or other solvent will comprise enough solvent mixture as to provide a liquid electrolyte with dissolved salt which permeates the cell separator. Such a minimal amount of cosolvent from a practical standpoint has been found to be about 10% by weight relative to the other solvent used. However, it is to be understood that this is not critical and any amount greater than zero percent by weight will provide some advantages of the invention. Likewise, there is no critical amount as to an upper limit, it being understood that any amount less than 100% cosolvent will accomplish some of the desirable aspects of the invention more or less. Again, from the practical standpoint, a useful upper limit has been found to be about 60% - 75% by weight for practical purposes. Preferred ranges are: 30 - 50% cosolvent, (as low as about 10% being acceptable) balance solvent. A preferred amount is about 40% cosolvent, balance solvent.

In its more general aspects, the invention is applicable to cells in which the anode comprises any active metal above hydrogen in the EMF series, preferably an alkali or alkaling earth metal or aluminum, most preferably lithium.

Typical cathode materials are solid and comprise as active components thereof metal oxides such as vanadium oxide (V $_6O_{13}$)silver vanadium oxide (Ag $_2$ V $_4O_{11}$)and manganese dioxide, the latter being preferred, thermally treated electrolytic manganese dioxide being most preferred, and may also comprise carbon monofluoride (CF $_x$) and hybrids e.g., CF $_x$ + MnO $_2$ and any other known active electrolytic components in combination, such as

10

15

20

combinations of those above. By "solid" with respect to those cathodes, it is meant to describe and refer to the pressed porous solid cathodes as are already known. Such cathodes are typically -made by mixing one or more of the active components, with carbon and poly (tetrafluorethylene) and pressing them to form a porous solid structure.

The separator is preferably microporous polypropylene bonded to a non-woven polypropylene substrate such as that provided by Celanese Corporation under the tradename CELGARD. However, non-woven polypropylene or other separator materials i.e., pressed fibers, may be used.

The non-aqueous electrolyte will be comprised of a salt of the anode metal having complex anions when dissolved in an organic solvent(s) and the cojolvent(s) of the invention. A preferred salt in the case of a lithium anode is lithium erchlorate. A preferred solvent/cosolvent is propylene carbonate with diglyme, ethyl diglyme or a mixture thereof.

Other electrolyte salts include but are not limited to: lithium trifluoroacetate, LIPF₆ LICF₃SO₃, LiBF₄, LiAsF₆.

Other solvents include but are not limited to: dioxolane, dimethyl sulfoxide, sulfolane and gammabutyrolactone.

In some instances, it may be useful to regard a mixture of diglyme and ethyl diglyme as constituting a cosolvent mixture to be used with propylene carbonate or the like.

The following examples illustrate various preferred embodiments. They are provided for illustrative purposes only and are included as a clarification of the invention and should not be considered as a limitation thereof. All parts are parts by weight unless otherwise indicated.

10

15

A. CELL CONSTRUCTION

The formation of methane was observed in cathode-limited cells of 2.7 Ah capacity. These were constructed in flat half round configured cases made of stainless steel 304L with external dimensions 5.2 x 3.0 x 0.6 cm. The cell consisted of a central lithium anode sandwiched between cathode pellets. The cathode consisted of 91.8 weight % of a thermally-treated electrolytic Mno₂ obtained from Mitsui Corporation, 5.0 weight % Shawninigan acetylene black and 3.2 weight % poly(tetrafluoroethylene). Each cell contains a total of 10.4 g of cathode material and 2.6-2.8 g of electrolyte. The area of the anode was 20 cm². Cathode pellets were vacuum-baked for 16 hours at 275°C immediately before assembly in a dry room maintained at less than about 1% relative humidity. The cases were made hermetic by welding the top in place.

After the cells had been discharged rapidly (0.2 mA/cm²) to about 2 Ah at 37°C, the current was relaxed to about 0.004 mA/cm². Within a few weeks, the relatively large flat faces or sides of the cells began to bulge under pressure. Cells were punctured in a small vacuum chamber. On the basis of data taken by mass spectrometry, gas chromatography and infrared spectroscopy, it was concluded that the gas was methane.

Definition of terms:

Glyme - also known as methyl glyme; methyl monoglyme; monoglyme;
 1,2-dimethoxyethane; 1,2-ethanediol dimethyl ether; ethylene glycol dimethyl ether. CAS #
 110-71-4.

- 2. Diglyme also known as methyl diglyme; 2-methoxyethyl ether; bis(2-methoxyethyl) ether; diethylene glycol dimethyl ether. CAS # 111-96-6.
- 3. Ethyl glyme also known as ethyl monoglyme; 1,2-diethoxyethane; 1,2-ethanediol diethyl ether; ethylene glycol diethyl ether. CAS # 112-36-7
- 4. Ethyl diglyme also known as 2-ethoxyethyl ether; bis(2-ethoxyethyl) ether; diethylene glycol diethyl ether; diethyl carbitol. CAS # 112-36-7
 - 5. Triglyme also known as methyl triglyme; triethylene glycol dimethyl ether; 1,2 (2-methoxyethoxy) ethane. CAS # 112-49-2.
 - 6. Tetraglyme also known as tetraethylene glycol dimethyl ether; 2, 5, 8, 11, 14-pentaoxapentadecane. CAS 143-24-8.
 - 7. Dimethoxymethane also known as formaldehyde dimethyl acetal; methylal. CAS # 109-87-5.
 - 8. 1,2-dimethoxypropane also known as propylene glycoldimethyl ether. CAS #7778-85-0.
- 9. 2,5-dimethoxytetrahydrofuran also known as dimethoxy THF; tetrahydro 2,5-dimethoxyfuran. CAS #7778-85-0.

B. SPECIFIC EXAMPLES

An electrolyte widely used in the battery industry is comprised of 1.0 molar LiCiO₄ in 50 volume % propylene carbonate / 50 volume % glyme. The examples are taken from experiments designed to investigate factors which affect the reactions which lead to the formation of methane mentioned above. Thus, many of the cells have been constructed with

electrolytes or tested under conditions which actually hasten or amplify the formation of methane. such experimental constructions and conditions include high levels of ether, addition of water, or elevated temperature discharge.

5

10

15

EXAMPLE I

In this example, cells as described above were filled with electrolyte composed of 1.0 M LiClO₄ in 50 volume % distilled glycol ether where the glycol ether in each of several cells is methyl glyme, methyl diglyme, ethyl glyme, or ethyl diglyme. The cells also contained 10 mg. water which was added to the cathode elements prior to cell construction. The cells were discharged as described above at 37°C. As shown in Figure 1, the flat sides of the cells initially pull in or contract during discharge due to the negative volume of the Li/MnO₂ reaction.

After about 300 days, the cell containing ethyl glyme 14 had swollen to its original thickness due to gas formation. See 10, 12, 14 and 16 in Fig. 1 respectively. After about 500 days, the methyl glyme cell 10 had swollen to its original thickness. After 570 days the cell capacity was depleted, and the cells containing ethyl diglyme 16 and methyl diglyme 12 had not increased in thickness.

EXAMPLE II

20

This example is the same as I, except the electrolytes are composed of 1.0 M LiClO₄ in 25 volume % PC / 75% distilled glycol ether. As shown in Figure 2, after 35 days, the methyl glyme cell 10 had swollen beyond its original thickness, followed by ethyl glyme

14 at 265 days, once again, ethyl diglyme 16 and methyl diglyme 12 cells did not increase in thickness during the course of discharge 570 days even though the reaction with methyl and ethyl glyme is much accelerated over example I.

5

EXAMPLE III

This example is the same as I, except the cells were discharged at 60°C. As shown in Fig. 3, the cell containing ethyl glyme 14 began swelling after 30 days, followed by methyl glyme 10 (202 days) and ethyl diglyme 16 (207 days). The cell containing methyl diglyme 12 did not swell throughout discharge (470 days).

10

15

EXAMPLE IV

This example is the same as I, except the cells were discharged at 60°C. As shown in Fig 4, after 18 days, the cells containing methyl glyme 10 and ethyl glyme 14 began swelling followed by ethyl diglyme 16 (60 days) and finally methyl diglyme 12 (390 days).

Fig. 5 shows cell voltage vs. discharged capacity for the cells of this Example IV. The voltage for the ethyl glyme 14 cell begins to deteriorate after about 70%, as does the methyl glyme 10 cell's voltage. The ethyl diglyme 16 cell begins deteriorating at about 75%. The methyl diglyme cell 12 shows very little voltage degradation to about 100% stoichiometric cell capacity.

10

15

20

EXAMPLE V

This example is analogous to Example II, with the exception that the glycol ethers are undistilled. As shown in Fig. 6 the cell containing ethyl glyme 14 began swelling immediately followed by methyl glyme 10 (35 days) and ethyl diglyme 16 (400 days). The methyl diglyme cell 12 did not swell over 590 days.

EXAMPLE VI

This example is the same as V except the cells were discharged at 60' C. As shown in Fig. 7, the ethyl glyme cell 14 began swelling immediately followed by methyl glyme 10 (18 days), ethyl diglyme 16 (60 days) and methyl diglyme 12 (750 days).

EXAMPLE VII

In this example, cells as described above were filled with electrolyte composed of 1.ON LiClO₄ in 25 volume % propylene carbonate (PC) / 75 volume % undistilled glycol ether where the glycol ether is methyl glyme or methyl diglyme. The cells contained not added water. The cells were discharged as described above at 37, 60 or 100°C. The results in Fig. 8 shows the cells containing methyl diglyme (12a/37°C, 12b/60°C and 12c/100°C) do not swell at or below 60°C. over the course of discharge, whereas cells containing methyl glyme (10a/37°C, 10b/60°C and 10c/100°C) do swell under the same conditions.

SUBSTITUTE SHEET

BNSDOCID: <WO____9202967A1_I_>

EXAMPLE VIII

In this example, cells as described above were filled with electrolyte composed of 1.OM LiClO₄ in 25 volume % propylene carbonate (PC) / 75 volume % undistilled glycol ether where the glycol ether is methyl glyme, methyl diglyme, triglyme, or tetraglyme. The cells also contained 10 mg. water which was added to the cathode elements prior to cell construction. The cells were discharged as described above at 37°C. Fig. 9 shows that only the cells containing methyl glyme 10 swelled under these conditions; the methyl diglyme 12, triglyme 18 and tetraglyme 20 cells did not.

10

5

EXAMPLE IX

In this example, cells as described above were filled with electrolyte composed of 1.OM

LiClO₄ in 25 volume % propylene carbonate (PC) / 75 volume % undistilled glycol ether where the glycol ether is dimethyoxyethane, dimethoxyethane, 1,2-dimethoxypropane, dimethoxy THF, or methyl diglyme. The cells also contained 10 mg. water which was added to the cathode elements prior to cell construction. The cells were discharged as described above at 37°C. As seen in Fig. 10, after a short time, the cell with dimethoxyethane 22 began swelling followed by the dimethoxymethane 24 (390 days) and dimethorypropane 26 cell. The cells containing dinethoxy THF 28 and diglyme 12 did not swell throughout discharge (550 days) as shown in Fig. 10.

20

14

EXAMPLE X

In this example, several cells as described above were filled with electrolyte composed of 1.OM LiClO₄ in 50 volume % PC / 50 volume % methyl diglyme. No water was added, and the cells were discharged at 75 microamperes at 37°C. Even after over four years of discharge, all the cells are at or below their initial thicknesses as shown in Fig. 11.

While preferred embodiments have been described in detail, this has not been done for purposes of limitation but by way of illustration. The invention is intended to be defined by the following claims:


SUBSTITUTE SHEET

BNSDOCID: <WO_____9202967A1_I_>


WHAT IS CLAIMED IS:

- 1. In an non-aqueous electrochemical cell of the type including an active metal anode, a porous solid cathode, a separator between the anode and cathode and a liquid electrolyte wetting the separator and in contact with the anode and cathode, wherein the electrolyte comprises a salt of the anode metal dissolved in an organic solvent, the improvement comprising the addition as a cosolvent with the solvent, of a quantity of cosolvent selected from the group consisting of diglyme; ethyl diglyme; ethylglyme; triglyme, tetraglyme and higher glymes; dimethyoxymethane; 1,2-dimethoxypropane; dimethoxy THF and mixtures thereof.
- 10 2. The cell of claim 1 in which the solvent/cosolvent is a diglyme/ethyl diglyme mixture or an ethyl diglyme/diglyne mixture per se.
 - 3. The cell of claim 1 in which the anode comprises lithium.
 - 4. The cell of claim 3 in which the cathode comprises manganese dioxide.
 - 5. The cell of claim 3 in which the cathode comprises silver vanadium oxide.
- 15 6. The cell of claim 4 in which the solvent is propylene carbonate.
 - 7. The cell of claim 6 in which the salt is lithium perchlorate.
 - 8. The cell of claim 1 in which the relative amounts of cosolvent and solvent by weight percentage range from about 10% cosolvent, balance solvent, to about 75% cosolvent, balance solvent.
- 20 9. The cell of claim 1 in which the cosolvent comprises diglyme.
 - 10. The cell of claim 1 in which the cosolvent comprises ethyl diglyne.

- 11. The cell of claim 1 in which the anode comprises lithium, the cathode comprises manganese dioxide, the electrolyte salt comprises lithium perchlorate and the solvent comprises propylene carbonate.
- 12. The cell of claim 1 in which the cathode comprises silver vanadium oxide.
- 5 13. The cell of Claim 1 in which the cathode comprises vanadium oxide.
 - 14. The cell of Claim 1 in which the cathode comprises CF_x.
 - 15. The cell of Claim 1 in which the cathode comprises a hybrid including CF_x , Mno_2 . V_6O_{13} , $Ag_2V_4O_{11}$.





SUBSTITUTE SHEET




SUBSTITUTE SHEET









SUBSTITUTE SHEET











8/11




SUBSTITUTE SHEET


9/11



SUBSTITUTE SHEET



SUBSTITUTE SHEET



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 91/05618

		international Application to 1 C	
		f several classification symbols apply, indicate all) ⁶	
	ing to International Patent Classification (I H 01 M 6/16	PC) or to both National Classification and IPC	····
II. FIEL	DS SEARCHED Mi	nimum Documentation Searched 7	
Classific	ation System	Classification Symbols	
IPC5	H 01 M		
		Searched other than Minimum Documentation such Documents are included in Fields Searched ⁸	•
	•		
III. DOC	UMENTS CONSIDERED TO BE RELEVA	NT'	
Category	 Citation of Document,¹¹ with indica 	ition, where appropriate, of the relevant passages 12	Relevant to Claim No.13
X	EP, A2, 0241644 (VARTA		1,3,4,6-
	AKTIENGESELLSCHAFT) see column 1, line		9,11
Υ	see Cordina 1, Trace	: 22 - 1 me 41	5,12-
			15
X	DE, C2, 2801160 (SAFT-L		1,3,6-9
	line 18	column 2, line 13 -	
	ine 10		
Χ	EP, A1, 0329271 (EASTMA	N KODAK COMPANY)	1,3,4,6,
	23 August 1989, see	page 2, line 40 -	8
	line 50		
	ial categories of cited documents: 10	t which is not "T" later document published after or priority date and not in concited to understand the princip	r the international filing date flict with the application but
	cument defining the general state of the ar nsidered to be of particular relevance riler document but published on or after th	inventional	
្រា	ng date	cannot be considered novel or	ce, the claimed invention cannot be considered to
-L" doi wh cit	cument which may throw doubts on priority ich is cited to establish the publication dat ation or other special reason (as specified)	e of another "Y" document of particular relevan	ice, the claimed invention e an inventive step when the
"O" do	cument referring to an oral disclosure, use ler means	exhibition or document is combined with on ments, such combination bein	e or more other such docu-
	cument published prior to the international er than the priority date claimed	in the art.	-
	FICATION		
Date of the	Actual Completion of the International Se		Search Report
6th D	ecember 1991	- 6. 01, 92	
nternation	al Searching Authority	Signature of Authorized Officer	
	EUROPEAN PATENT OFFICE	M. PEIS	.Pe's
PCT/IS	A/210 (second sheet) (January 1985)		

	IMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)	Relevant to Claim No
ategory *	Citation of Document, with Indication, where appropriate, of the relevant passages	Relevant to Claim No
	DE, A1, 2926666 (EXXON RESEARCH AND ENGINEERING CO) 14 May 1980,	1,3,6,8, 9,14
,	see page 7, line 20 - line 22	14
,	US, A, 4310609 (CHARLES C. LIANG ET AL) 12 January 1982, see column 6, line 27 - line 50	12,13, 15
1	GB, A, 2135814 (DURACELL INC (USA-DELAWARE)) 5 September 1984, see the whole document	1-15
		
	·	
	·	
	•	
	·	
į		
•		
	-	
Ī		
ļ	A/210 (extra sheet) (January 1985)	<u> </u>

BNSDOCID: <WO_____9202967A1_I_>

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.PCT/US 91/05618

SA 51678

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on

The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report		Publication date	Patent family member(s)		Publication date	
EP-A2- 0241644 -	21/10/87	DE-A- JP-A- US-A-	3611123 62237680 4713305	08/10/87 17/10/87 15/12/87		
DE-C2-	2801160	26/08/82	AU-B- AU-D- BE-A- CA-A- CH-A- FR-A-B- GB-A- JP-A- JP-B- JP-A- NL-A- US-A-	508518 3244178 862809 1102101 627302 2378361 1543303 53089941 57009669 59012570 7800681 4129691	20/03/80 26/07/79 11/07/78 02/06/81 31/12/81 18/08/78 04/04/79 08/08/78 23/02/82 23/01/84 21/07/78 12/12/78	
EP-A1-	0329271	23/08/89	JP-A- US-A-	1213962 4804595	28/08/89 14/02/89	
DE-A1-	2926666	14/05/80	BE-A- CA-A- CH-A- FR-A- GB-A-B- JP-A- NL-A- US-A-	877406 1120534 642778 2440623 2033137 55060276 7905137 4248946	02/01/80 23/03/82 30/04/84 30/05/80 14/05/80 07/05/80 02/05/80 03/02/81	
US-A-	4310609	12/01/82	AU-B- AU-D- CA-A- DE-A- FR-A-B- GB-A-B- JP-B- JP-C- JP-A- NL-A- SE-B-C- SE-A- US-A-	541718 6119580 1147385 3031554 2471673 2065957 1028464 1545264 56093266 8006638 451920 8005496 4391729	17/01/85 25/06/81 31/05/83 25/06/81 19/06/81 01/07/81 02/06/89 15/02/90 28/07/81 16/07/81 02/11/87 18/06/81 05/07/83	
GB-A-	2135814	05/09/84	DE-A-	3405610	16/08/84	

For more details about this annex : see Official Journal of the European patent Office, No. 12/82

EPO FORM P0479

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.PCT/US 91/05618

SA

51678

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 27/09/91

The European Patent office is in no way liable for theseparticulars which are merely given for the purpose of information.

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
B-A-	2135814	05/09/84	FR-A-B- JP-A- US-A-	2541045 59214163 4482613	17/08/84 04/12/84 13/11/84
	1				
				•	
	•				
		·			

For more details about this annex: see Official Journal of the European patent Office, No. 12/82

EPO FORM P0479

PCT

(30) Priority data:

566,010

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

H01M 6/16

(11) International Publication Number: WO 92/0296

A1

(43) International Publication Date: 20 February 1992 (20.02.92)

US

(21) International Application Number: PCT/US91/05618

(22) International Filing Date: 7 August 1991 (07.08.91)

(71) Applicant: MEDTRONIC, INC. IUS/USI: 7000 Central

10 August 1990 (10.08.90)

(71) Applicant: MEDTRONIC, INC. [US/US]; 7000 Central Avenue N.E., Minneapolis, MN 55432 (US).

(72) Inventors: BERBERICK, David, K.; 10177 Nathan Lane, Maple Grove, MN 55369 (US). CRETZMEYER, John, W.; 7604 Oliver Avenue South, Richfield, MN 55423 (US). MERRITT, Donald, R.; 3806 Woodbine Lane, Brookyln Center, MN 55429 (US). SKARSTAD, Paul, M.; 2415 Graland Lane, Plymouth, MN 55447 (US). WEISS, Douglas, J.; 3742 114th Lane Northwest, Coon Rapids, MN 55433 (US).

(74) Agents: LATHAM, Daniel, W. et al.; Medtronic, Inc 7000 Central Avenue N.E., Minneapolis, MN 5543 (US).

(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GI (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).


Published

With international search report. With amended claims.

Date of publication of the amended claims:

4 March 1993 (04.03.93

(54) Title: IMPROVED ELECTROLYTE FOR LITHIUM-MANGANESE OXIDE CELLS AND THE LIKE



(57) Abstract

An improved electrolyte for electrochemical cells including as a cosolvent for the cell electrolyte salt an amount of diglyme; ethyl diglyme; ethyl glyme; triglyme, tetraglyme and higher glymes; dimethoxymethane; 1,2-dimethoxypropane; dimethoxy THF or mixtures thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCI on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gahon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinca	NO	Norway
BC	Bulgaria	GR	Greece	NZ	New Zealand
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	ΙE	Ircland	PT	Portugal
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	lapan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic	SD	Sudan
CH	Switzerland		of Korea	SE	Sweden
CI	Côte d'Ivoire	KR	Republic of Korea	SK	Slovak Republic
		Li	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
ΘE	Germany	MG MG		UA	Ukraine
ÐK	Denmark		Madagascar	US	United States of America
ES	Spain	Mi	Mali	03	


AMENDED CLAIMS

[received by the International Bureau on 26 February 1992 (26.02.92); original claims 4, 5, 12 and 13 cancelled; original claims land 2 amended;


original claims 6, 7 and 14 replaced by amended claims 4, 5 and 10; claims 8-11 and 15 unchanged but renumbered as claims 6-9 and 11; claim 3 unchanged (2 pages)]

- 1. In a hermetically sealed non-aqueous electrochemical cell including an active metal anode, a porous solid cathode having a cathode material selected from the group consisting of MnO_2 , silver vanadium oxide, and V_6O_{13} , a separator between the anode and cathode and a liquid electrolyte wetting the separator and in contact with the anode and cathode, wherein the electrolyte comprises a salt of the anode metal dissolved in an organic solvent, the improvement comprising the addition as a cosolvent with the solvent, of a quantity of cosolvent selected from the group consisting of diglyme, ethyl diglyme, ethylglyme, triglyme, tetraglyme, dimethoxymethane, 1,2-dimethoxypropane, 2,5-dimethoxytetrahydrofuran and mixtures thereof.
- 2. The cell of claim 1 in which the solvent/cosolvent is a diglyme/ethyl diglyme mixture or an ethyl diglyme/diglyme mixture.
- 3. The cell of claim 1 in which the anode comprises lithium.
- 4. The cell of claim 3 in which the solvent is propylene carbonate.
- 5. The cell of claim 4 in which the salt is lithium perchlorate.
- 6. The cell of claim 1 in which the relative amounts of cosolvent and solvent by weight percentage range from about 10% cosolvent, balance solvent, to about 75% cosolvent, balance solvent.

- 7. The cell of claim 1 in which the cosolvent comprises diglyme.
- 8. The cell of claim 1 in which the cosolvent comprises ethyl diglyme.
- 9. The cell of claim 1 in which the anode comprises lithium, the cathode comprises manganese dioxide, the electrolyte salt comprises lithium perchlorate and the solvent comprises propylene carbonate.
- 10. The cell of claim 1 in which the cathode also comprises $CF_{\mathbf{x}}$.
- 11. The cell of claim 1 in which the cathode comprise a hybrid including CF_x , MnO_2 , V_6O_{13} , $Ag_2V_4O_{11}$.





SUBSTITUTE SHEET



SUBSTITUTE SHEET









SUBSTITUTE SHEET






SUBSTITUTE SHEET


6/11




SUBSTITUTE SHEET




SUBSTITUTE SHEET



SUBSTITUTE SHEET




SUBSTITUTE SHEET



SUBSTITUTE SHEET

11/11



SUBSTITUTE SHEET

THIS PAGE BLANK (USPTO)

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.